Insulet Corporation $PODD Shares Acquired by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp increased its stake in Insulet Corporation by 10.5% during the first quarter, purchasing an additional 884 shares to bring its total to 9,313 shares, valued at approximately $2.4 million.
• Insulet's latest earnings report revealed an EPS of $1.17, surpassing estimates of $0.92, with a revenue increase of 32.9% year-over-year.
• Analysts have issued a majority buy rating for Insulet, with the average target price currently set at $332.71, reflecting positive sentiment around the company's growth potential.

OMERS ADMINISTRATION Corp lifted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 10.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,313 shares of the medical instruments supplier's stock after buying an additional 884 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Insulet were worth $2,446,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. American Century Companies Inc. raised its position in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment lifted its position in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after acquiring an additional 3,759 shares in the last quarter. Northern Trust Corp raised its position in shares of Insulet by 20.5% in the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock valued at $192,881,000 after buying an additional 125,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after purchasing an additional 27,408 shares during the last quarter.

Insulet Stock Down 1.1%

Insulet stock traded down $3.92 during trading on Wednesday, reaching $341.01. The stock had a trading volume of 335,701 shares, compared to its average volume of 755,035. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 52-week low of $204.02 and a 52-week high of $350.00. The stock has a market cap of $24.00 billion, a PE ratio of 103.61, a P/E/G ratio of 2.85 and a beta of 1.36. The business has a 50 day moving average price of $305.37 and a 200 day moving average price of $288.52.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's revenue was up 32.9% on a year-over-year basis. During the same period last year, the business earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of several research analyst reports. Royal Bank Of Canada increased their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price for the company in a report on Tuesday, May 13th. Wells Fargo & Company upped their price target on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $332.71.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.